NVNONVNOHealthcare · Medical Devices

NVNO Stock Forecast: enVVeno Medical Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$5.60
+0.54% on the day

The median 12-month analyst price target for enVVeno Medical Corp. is $30. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$3.9M
Ticker Nerd rank
28/ 100
Median analyst target
$30
Analysts covering
1
Revenue$0.0
Operating income−$3.8M
Net income−$3.6M
Free cash flow−$3.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.2%
1M
−27.3%
YTD
−50.2%
1Y
−50.5%
From 52W high
−59.8%
From 52W low
+0.5%
$6
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores enVVeno Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
28/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Accruals
77
Issuance
48
Volatility
26
Revisions
20
Quality
18
Momentum
7
Value
4

Growth (86): Sales and profits are climbing, and climbing faster than before.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NVNO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVNO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26NVNOHigh $30Median $30Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$30
Low
$30
Median
$30
High

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NVNO.

Market Radar

This page is one stock. Monday covers all of them.

NVNO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NVNO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, enVVeno Medical Corp. returned −50.5% against +6.9% for the S&P 500, dividends included.

NVNO vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26NVNOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NVNO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.2×

Cheaper than 93% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−67.1%

Higher than 18% of US stocks

Return on assets
−40.4%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • enVVeno Medical Corp. has a market value of $3.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$15.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.6M.

  • Shares outstanding: 655,521.

  • enVVeno Medical Corp. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NVNO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NVNOenVVeno Medical Corp.$3.9M28
ICCMIceCure Medical Ltd.$4.5M30
INBSIntelligent Bio Solutions, Inc.$4.6M21
WOKWORK Medical Technology Group Ltd.$4.9M16
BMRABiomerica, Inc.$5.0M11
BDMDBaird Medical Investment Holdings Ltd.$5.1M59
POASPhaos Technology Holdings (Cayman) Ltd.$5.1M2

Take a look at NVNO’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own enVVeno Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NVNO

What is the NVNO stock price forecast for 2026-2027?

The median 12-month analyst price target for enVVeno Medical Corp. is $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVNO stock a buy right now?

Of the 1 analyst covering enVVeno Medical Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks enVVeno Medical Corp. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVNO?

As at 21 Nov 2026, enVVeno Medical Corp. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will NVNO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $30, and Ticker Nerd's factor model ranks enVVeno Medical Corp. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVNO stock forecast for 2030?

No analyst covering enVVeno Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVNO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has NVNO stock performed over the past year?

enVVeno Medical Corp. returned -50.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does enVVeno Medical Corp. do?

enVVeno Medical Corporation is a medical device company focused on developing bioprosthetic, tissue-based solutions for venous disease. The company’s current portfolio centers on the VenoValve, a surgical replacement venous valve designed for patients with deep venous chronic venous insufficiency, and enVVe, a non-surgical, transcatheter-based venous valve system under development.

Company

About enVVeno Medical Corp.

enVVeno Medical Corporation is a medical device company focused on developing bioprosthetic, tissue-based solutions for venous disease. The company’s current portfolio centers on the VenoValve, a surgical replacement venous valve designed for patients with deep venous chronic venous insufficiency, and enVVe, a non-surgical, transcatheter-based venous valve system under development. These products are intended to address valve failure in the deep venous system and support more effective blood flow in patients with chronic venous disorders. enVVeno Medical Corporation serves the broader vascular medicine market, where it aims to improve treatment options for conditions that can cause pain, swelling, and long-term circulatory problems. Based in Irvine, California and incorporated in 1999, the company remains a late clinical-stage player in specialized medical technology, with a business model centered on advancing implantable and minimally invasive venous care solutions.

CEO Mr. Robert A. Berman · 33 employees · United States · https://www.envveno.com